Passive immunization in JNPL3 transgenic mice using an array of phospho-tau specific antibodies

PLoS ONE

Volumn 10, Issue 8, 2015, Pages

  D'Abramo, Cristina ^a   Acker, Christopher M ^a   Jimenez, Heidy ^a   Davies, Peter ^a  

^a FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; MONOCLONAL ANTIBODY; SODIUM CHLORIDE; TAU MONOCLONAL ANTIBODY; TAU PROTEIN; UNCLASSIFIED DRUG; PHOSPHOSPECIFIC ANTIBODY;

ADULT; ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY SPECIFICITY; ARTICLE; BRAIN CORTEX; CONTROLLED STUDY; FEMALE; HIPPOCAMPUS; IMMUNOCYTOCHEMISTRY; MOUSE; NONHUMAN; PASSIVE IMMUNIZATION; PROTEIN AGGREGATION; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; RHOMBENCEPHALON; TAUOPATHY; TRANSGENIC MOUSE; ANIMAL; DISEASE MODEL; DRUG EFFECTS; GENETICS; HUMAN; IMMUNOLOGY; INTRAPERITONEAL DRUG ADMINISTRATION; METABOLISM; PHOSPHORYLATION; PROCEDURES; TAUOPATHIES;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, PHOSPHO-SPECIFIC; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; IMMUNIZATION, PASSIVE; INJECTIONS, INTRAPERITONEAL; MICE; MICE, TRANSGENIC; PHOSPHORYLATION; RHOMBENCEPHALON; TAU PROTEINS; TAUOPATHIES;

EID: 84942852259     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0135774     Document Type: Article

References (34)

1. Hebert LE, Weuve J, Scherr PA, Evans DA. Alzheimer disease in the United States (2010-2050) estimated using the 2010 census. Neurology. 2013; 80(19):1778-83. doi: 10.1212/WNL. 0b013e31828726f5 PMID: 23390181; PubMed Central PMCID: PMCPMC3719424.
2. Arriagada PV, Growdon JH, Hedley-Whyte ET, Hyman BT. Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease. Neurology. 1992; 42(3 Pt 1):631-9. PMID: 1549228.
3. Braak H, Braak E. Diagnostic criteria for neuropathologic assessment of Alzheimer's disease. Neurobiol Aging. 1997; 18(4 Suppl):S85-8. PMID: 9330992.
4. Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991; 82(4):239-59. PMID: 1759558.
5. Braak H, Del Trecidi K. Neuroanatomy and pathology of sporadic Alzheimer's disease. Adv Anat Embryol Cell Biol. 2015; 215:1-162. PMID: 25920101.
6. Bancher C, Brunner C, Lassmann H, Budka H, Jellinger K, Wiche G, et al. Accumulation of abnormally phosphorylated tau precedes the formation of neurofibrillary tangles in Alzheimer's disease. Brain Res. 1989; 477(1-2):90-9. PMID: 2495152.
7. Kovacech B, Skrabana R, Novak M. Transition of tau protein from disordered to misordered in Alzheimer's disease. Neurodegener Dis. 2010; 7(1-3):24-7. doi: 10.1159/000283478 PMID: 20160453.
8. Uchihara T, Nakamura A, Yamazaki M, Mori O. Evolution from pretangle neurons to neurofibrillary tangles monitored by thiazin red combined with Gallyas method and double immunofluorescence. Acta Neuropathol. 2001; 101(6):535-9. PMID: 11515780.
9. Clavaguera F, Bolmont T, Crowther RA, Abramowski D, Frank S, Probst A, et al. Transmission and spreading of tauopathy in transgenic mouse brain. Nat Cell Biol. 2009; 11(7):909-13. doi: 10.1038/ncb1901 PMID: 19503072; PubMed Central PMCID: PMCPMC2726961.
10. Frost B, Jacks RL, Diamond MI. Propagation of tau misfolding from the outside to the inside of a cell. J Biol Chem. 2009; 284(19):12845-52. Epub 2009/03/14. doi: M808759200 [pii] doi: 10.1074/jbc.M808759200 PMID: 19282288; PubMed Central PMCID: PMC2676015.
11. Kfoury N, Holmes BB, Jiang H, Holtzman DM, Diamond MI. Trans-cellular Propagation of Tau Aggregation by Fibrillar Species. J Biol Chem. 2012; 287(23):19440-51. Epub 2012/03/31. doi: M112.346072 [pii] doi: 10.1074/jbc.M112.346072 PMID: 22461630; PubMed Central PMCID: PMC3365982.
12. Wu JW, Herman M, Liu L, Simoes S, Acker CM, Figueroa H, et al. Small misfolded Tau species are internalized via bulk endocytosis and anterogradely and retrogradely transported in neurons. J Biol Chem. 2013; 288(3):1856-70. Epub 2012/11/29. doi: M112.394528 [pii] doi: 10.1074/jbc.M112.394528 PMID: 23188818; PubMed Central PMCID: PMC3548495.
13. de Calignon A, Polydoro M, Suárez-Calvet M, William C, Adamowicz DH, Kopeikina KJ, et al. Propagation of tau pathology in a model of early Alzheimer's disease. Neuron. 2012; 73(4):685-97. doi: 10.1016/j.neuron.2011.11.033 PMID: 22365544; PubMed Central PMCID: PMCPMC3292759.
14. Holmes BB, Furman JL, Mahan TE, Yamasaki TR, Mirbaha H, Eades WC, et al. Proteopathic tau seeding predicts tauopathy in vivo. Proc Natl Acad Sci U S A. 2014; 111(41):E4376-85. doi: 10.1073/pnas.1411649111 PMID: 25261551; PubMed Central PMCID: PMCPMC4205609.
15. Boutajangout A, Quartermain D, Sigurdsson EM. Immunotherapy targeting pathological tau prevents cognitive decline in a new tangle mouse model. J Neurosci. 2010; 30(49):16559-66. doi: 10.1523/JNEUROSCI.4363-10.2010 PMID: 21147995; PubMed Central PMCID: PMCPMC3135981.
16. Chai X, Wu S, Murray TK, Kinley R, Cella CV, Sims H, et al. Passive immunization with anti-Tau antibodies in two transgenic models: reduction of Tau pathology and delay of disease progression. J Biol Chem. 2011; 286(39):34457-67. doi: 10.1074/jbc.M111.229633 PMID: 21841002; PubMed Central PMCID: PMCPMC3190817.
17. d'Abramo C, Acker CM, Jimenez HT, Davies P. Tau passive immunotherapy in mutant P301L mice: antibody affinity versus specificity. PLoS One. 2013; 8(4):e62402. doi: 10.1371/journal.pone.0062402 MID: 23638068; PubMed Central PMCID: PMCPMC3639259.
18. Asuni AA, Boutajangout A, Quartermain D, Sigurdsson EM. Immunotherapy targeting pathological tau conformers in a tangle mouse model reduces brain pathology with associated functional improvements. J Neurosci. 2007; 27(34):9115-29. doi: 10.1523/JNEUROSCI.2361-07.2007 PMID: 17715348.
19. Yanamandra K, Kfoury N, Jiang H, Mahan TE, Ma S, Maloney SE, et al. Anti-tau antibodies that block tau aggregate seeding in vitro markedly decrease pathology and improve cognition in vivo. Neuron. 2013; 80(2):402-14. doi: 10.1016/j.neuron.2013.07.046 PMID: 24075978; PubMed Central PMCID: PMCPMC3924573.
20. Theunis C, Crespo-Biel N, Gafner V, Pihlgren M, López-Deber MP, Reis P, et al. Efficacy and safety of a liposome-based vaccine against protein Tau, assessed in tau.P301L mice that model tauopathy. PLoS One. 2013; 8(8):e72301. doi: 10.1371/journal.pone.0072301 PMID: 23977276; PubMed Central PMCID: PMCPMC3747157.
21. Sankaranarayanan S, Barten DM, Vana L, Devidze N, Yang L, Cadelina G, et al. Passive immunization with phospho-tau antibodies reduces tau pathology and functional deficits in two distinct mouse tauopathy models. PLoS One. 2015; 10(5):e0125614. doi: 10.1371/journal.pone.0125614 PMID: 25933020.
22. Yanamandra K, Jiang H, Mahan TE, Maloney SE, Wozniak DF, Diamond MI, et al. Anti-tau antibody reduces insoluble tau and decreases brain atrophy. Ann Clin Transl Neurol. 2015; 2(3):278-88. doi: 10.1002/acn3.176 PMID: 25815354; PubMed Central PMCID: PMCPMC4369277.
23. Troquier L, Caillierez R, Burnouf S, Fernandez-Gomez FJ, Grosjean ME, Zommer N, et al. Targeting phospho-Ser422 by active Tau Immunotherapy in the THYTau22 mouse model: a suitable therapeutic approach. Curr Alzheimer Res. 2012; 9(4):397-405. PMID: 22272619; PubMed Central PMCID: PMCPMC3637173.
24. Boutajangout A, Ingadottir J, Davies P, Sigurdsson EM. Passive immunization targeting pathological phospho-tau protein in a mouse model reduces functional decline and clears tau aggregates from the brain. J Neurochem. 2011; 118(4):658-67. doi: 10.1111/j.1471-4159.2011.07337.x PMID: 21644996; PubMed Central PMCID: PMCPMC3366469.
25. Acker CM, Forest SK, Zinkowski R, Davies P, d'Abramo C. Sensitive quantitative assays for tau and phospho-tau in transgenic mouse models. Neurobiol Aging. 2012. Epub 2012/06/26. doi: 10.1016/j.neurobiolaging.2012.05.010 PMID: 22727277.
26. Jicha GA, Berenfeld B, Davies P. Sequence requirements for formation of conformational variants of tau similar to those found in Alzheimer's disease. J Neurosci Res. 1999; 55(6):713-23. PMID: 10220112.
27. Acker CM, Forest SK, Zinkowski R, Davies P, d'Abramo C. Sensitive quantitative assays for tau and phospho-tau in transgenic mouse models. Neurobiol Aging. 2013; 34(1):338-50. doi: 10.1016/j.neurobiolaging.2012.05.010 PMID: 22727277; PubMed Central PMCID: PMCPMC3474864.
28. Noble W, Olm V, Takata K, Casey E, Mary O, Meyerson J, et al. Cdk5 is a key factor in tau aggregation and tangle formation in vivo. Neuron. 2003; 38(4):555-65. Epub 2003/05/27. PMID: 12765608.
29. Davies P. Characterization and use of monoclonal antibodies to tau and paired helical filament tau. Methods Mol Med. 2000; 32:361-73. Epub 2000/01/01. doi: 10.1385/1-59259-195-7:361 PMID: 21318532.
30. Andorfer C, Kress Y, Espinoza M, de Silva R, Tucker KL, Barde YA, et al. Hyperphosphorylation and aggregation of tau in mice expressing normal human tau isoforms. J Neurochem. 2003; 86(3):582-90. Epub 2003/07/16. PMID: 12859672.
31. Andorfer C, Acker CM, Kress Y, Hof PR, Duff K, Davies P. Cell-cycle reentry and cell death in transgenic mice expressing nonmutant human tau isoforms. J Neurosci. 2005; 25(22):5446-54. Epub 2005/06/03. doi: 10.1523/JNEUROSCI.4637-04.2005 PMID: 15930395.
32. Forest SK, Acker CM, d'Abramo C, Davies P. Methods for Measuring Tau Pathology in Transgenic Mouse Models. J Alzheimers Dis. 2012. Epub 2012/09/15. doi: 10.3233/JAD-2012-121354 PMID: 22976073.
33. Forest SK, Acker CM, d'Abramo C, Davies P. Methods for measuring tau pathology in transgenic mouse models. J Alzheimers Dis. 2013; 33(2):463-71. doi: 10.3233/JAD-2012-121354 PMID: 22976073; PubMed Central PMCID: PMCPMC3627375.
34. Pedersen JT, Sigurdsson EM. Tau immunotherapy for Alzheimer's disease. Trends Mol Med. 2015. doi: 10.1016/j.molmed.2015.03.003 PMID: 25846560.